Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AADAT | Q8N5Z0 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.77 |
| ▸ | GAA | P10253 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.68 |
| ▸ | POLB | P06746 | 3/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL392680 | 0.87 | ALDH1A1 (1.00) | AADATALDH1A1GAAKMT2AL3MBTL1 | |
| SCHEMBL478614 | 0.87 | ALDH1A1 (1.00) | AADATALDH1A1GAAKMT2AL3MBTL1 | |
| SCHEMBL30216480 | 0.87 | ALDH1A1 (1.00) | AADATALDH1A1GAAKMT2AL3MBTL1 | |
| SCHEMBL4861809 | 0.87 | ALDH1A1 (1.00) | AADATALDH1A1GAAKMT2AL3MBTL1 | |
| SCHEMBL9194175 | 0.86 | KMT2A (0.75) | AADATALDH1A1GAAKMT2AL3MBTL1 | |
| Hydrochloric Acid SCHEMBL7840775 | 0.86 | ALDH1A1 (0.97) | AADATALDH1A1GAAKMT2AL3MBTL1 | |
| SCHEMBL21914173 | 0.84 | AADAT (0.72) | AADATALDH1A1GAAKMT2AL3MBTL1 | |
| SCHEMBL2986755 | 0.82 | ALDH1A1 (0.77) | AADATALDH1A1GAAKMT2AL3MBTL1 | |
| SCHEMBL12643501 | 0.81 | ALDH1A1 (0.76) | AADATALDH1A1GAAKMT2AL3MBTL1 | |
| SCHEMBL9665050 | 0.79 | ALDH1A1 (0.78) | AADATALDH1A1GAAKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11324731-B2 | TXNIP-TRX complex inhibitors and methods of using the same | CITY OF HOPE (US) | 2022-05-10 | — | — | US | disclosed |
| US-20200085800-A1 | TXNIP-TRX COMPLEX INHIBITORS AND METHODS OF USING THE SAME | CITY OF HOPE | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11324731-B2 | TXNIP-TRX complex inhibitors and methods of using the same | TXN, TXN2, TXNRD3 | AADAT 1736/4885ALDH1A1 3479/4885GAA 4097/4885 |
| US-20200085800-A1 | TXNIP-TRX COMPLEX INHIBITORS AND METHODS OF USING THE SAME | TXN, TXN2, TXNRD3 | AADAT 1736/4885ALDH1A1 3479/4885GAA 4097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.